Identification of BTG2, an antiproliferative p53–dependent component of the DNA damage cellular response pathway JP Rouault, N Falette, F Guéhenneux, C Guillot, R Rimokh, Q Wang, ... Nature genetics 14 (4), 482-486, 1996 | 516 | 1996 |
p53 gene mutations in human epithelial skin cancers. JP Moles, C Moyret, B Guillot, P Jeanteur, JJ Guilhou, C Theillet, ... Oncogene 8 (3), 583-588, 1993 | 244 | 1993 |
Prognostic value of Dicer expression in human breast cancers and association with the mesenchymal phenotype G Grelier, N Voirin, AS Ay, DG Cox, S Chabaud, I Treilleux, ... British journal of cancer 101 (4), 673-683, 2009 | 232 | 2009 |
A stemness-related ZEB1–MSRB3 axis governs cellular pliancy and breast cancer genome stability AP Morel, C Ginestier, RM Pommier, O Cabaud, E Ruiz, J Wicinski, ... Nature medicine 23 (5), 568-578, 2017 | 159 | 2017 |
Alterations of anaphase-promoting complex genes in human colon cancer cells Q Wang, C Moyret-Lalle, F Couzon, C Surbiguet-Clippe, JC Saurin, ... Oncogene 22 (10), 1486-1490, 2003 | 141 | 2003 |
BTG gene expression in the p53‐dependent and ‐independent cellular response to DNA damage U Cortes, C Moyret‐Lalle, N Falette, C Duriez, FE Ghissassi, C Barnas, ... Molecular carcinogenesis 27 (2), 57-64, 2000 | 112 | 2000 |
Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene. C Moyret, C Theillet, PL Puig, JP Moles, G Thomas, R Hamelin Oncogene 9 (6), 1739-1743, 1994 | 111 | 1994 |
Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function Z Cai, C Capoulade, C Moyret-Lalle, M Amor-Gueret, J Feunteun, ... Oncogene 15 (23), 2817-2826, 1997 | 102 | 1997 |
ras, p53 and HPV status in benign and malignant prostate tumors C Moyret‐Lalle, C Marcais, J Jacquemier, JP Moles, A Daver, JY Soret, ... International journal of cancer 64 (2), 124-129, 1995 | 91 | 1995 |
The human BTG2/TIS21/PC3 gene: genomic structure, transcriptional regulation and evaluation as a candidate tumor suppressor gene C Duriez, N Falette, C Audoynaud, C Moyret-Lalle, K Bensaad, S Courtois, ... Gene 282 (1-2), 207-214, 2002 | 89 | 2002 |
Direct sequencing by thermal asymmetric PCR TC Mazars G, Moyret C, Jeanteur P Nucleic Acid Research 19 (17), 4738, 1991 | 79* | 1991 |
Epithelial-mesenchymal transition transcription factors and miRNAs:“Plastic surgeons” of breast cancer C Moyret-Lalle, E Ruiz, A Puisieux World journal of clinical oncology 5 (3), 311, 2014 | 72 | 2014 |
BTG2, its family and its tutor C Duriez, C Moyret-Lalle, N Falette, ELG Fatiha, A Puisieux Bulletin du Cancer 91 (7), 10242-10253, 2004 | 63 | 2004 |
Absence of p53-dependent induction of the metastatic suppressor KAI1 gene after DNA damage C Duriez, N Falette, U Cortes, C Moyret-Lalle, A Puisieux Oncogene 19 (20), 2461-2464, 2000 | 59 | 2000 |
Gradual selection of a cellular clone presenting a mutation at codon 179 of the p53 gene during establishment of the immortalized human breast epithelial cell line HMT-3522 C Moyret, MW Madsen, J Cooke, P Briand, C Theillet Experimental cell research 215 (2), 380-385, 1994 | 37 | 1994 |
Two germ-line mutations affecting the same nucleotide at codon 257 of p53 gene, a rare site for mutations. OM Mazoyer S, Lalle P, Moyret-Lalle C, Marçais C, Schraub S, Frappaz D, Sobol H Oncogene 9 (4), 1237-1239, 1994 | 35 | 1994 |
TIF1γ suppresses tumor progression by regulating mitotic checkpoints and chromosomal stability RM Pommier, J Gout, DF Vincent, LB Alcaraz, N Chuvin, V Arfi, S Martel, ... Cancer research 75 (20), 4335-4350, 2015 | 34 | 2015 |
p53 induction prevents accumulation of aberrant transcripts in cancer cells C Moyret-Lalle, C Duriez, J Van Kerckhove, C Gilbert, Q Wang, A Puisieux Cancer research 61 (2), 486-488, 2001 | 28 | 2001 |
Genomic stability and wild-type p53 function of lymphoblastoid cells with germ-line p53 mutation P Lalle, C Moyret-Lalle, Q Wang, JM Vialle, C Navarro, BB Paillerets, ... Oncogene 10 (12), 2447-2454, 1995 | 28 | 1995 |
EMT transcription factor ZEB1 represses the mutagenic POLθ-mediated end-joining pathway in breast cancers MK Prodhomme, RM Pommier, C Franchet, F Fauvet, V Bergoglio, ... Cancer Research 81 (6), 1595-1606, 2021 | 27 | 2021 |